NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024. Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company. The three-year agreement builds on the collaboration established in 2022. The agreement ...

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Ramy Farid - President and Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies LLC Malcolm Hoffman - BMO Capital Markets Michael Ryskin - Bank of America Securities, Inc. Matthew Hewitt - Craig- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 _____________________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies David Lebowitz - Citigroup Evan Seigerman - BMO Capital Markets Vikram Purohit - Morgan Stanley Matt Hewitt - Craig-Hallum Gaurav Goparaju - Berenberg Capital Markets Michael Ryskin - Bank of America Joseph Catanzaro - Pip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to (Mark One) Commission File Number: 001-39206 ________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR WASHINGTON, DC 20549 ________________________________________ Schrodinger, Inc. o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q ________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Vikram Purohit - Morgan Stanley David Lebowitz - Citi Chris Shibutani - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. Welcome to Schr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 ________________________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Do Kim - Piper Sandler David Lebowitz - Citi Gary Nachman - BMO Capital Markets Wolf Chanoff - Bank of America Operator Thank you for standing by. Welcome to Schröd ...

Enhanced Platform Capabilities • Initiated SGR-1505 Phase 1 trial Second Quarter 2022 Supplemental Slides February 28, 2023 Transforming Discovery of Therapeutics and Materials This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-K _______________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39206 _______________________________________ Schrod ...